Financial comparisons Perspective Therapeutics, Inc.
Stocks
CATX
US46489V3024
Biotechnology & Medical Research
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 3.010 USD | -5.05% |
|
-17.08% | +9.45% |
| 07-08 | Perspective Therapeutics, Inc. Announces Executive Changes | CI |
| 07-08 | Perspective Therapeutics Names Paul Lyne Chief Science Officer as Co-Founder Michael Schultz Moves to Advisory Role | MT |
Main competitors
| Revenues (Y-1) | Net Margin (Y-1) | EBIT Margin (Y-1) | ROE (Y-1) | ROA (Y-1) | Leverage (Y-1) | ||
|---|---|---|---|---|---|---|---|
 | 884K | -11,665.27% | -12,846.61% | -41.44% | - | 1.3x | |
| 8.24B | 14.53% | 21.7% | 10.28% | 4.9% | 1.58x | |
| 16.31B | 8.34% | 13.38% | 32.9% | 4.79% | 3.63x | |
| 5.34B | 5.37% | 8.37% | 29.84% | 16.27% | -5.99x | |
| 2.88B | 24.74% | 28.07% | 5.94% | 4.75% | 1.77x | |
| 846M | -31.67% | -18.92% | - | - | 1.57x | |
| 2.53B | 17.83% | 20.93% | 70.23% | 22.13% | -0.89x | |
| 8.57B | 6.51% | 14.79% | 9.61% | 4.34% | 2.22x | |
| 8.25B | 2.78% | 16.66% | 10.62% | 6.02% | 1.8x | |
| 5.4M | -7,306.52% | -5,350% | -135.58% | - | 2.1x | |
| 4.02B | -3.59% | 19.77% | 15.46% | 6.99% | 1.98x | |
| 1.22B | 6.02% | 31.45% | 15.37% | 11.65% | 0.43x | |
| 1.27B | -19.27% | -3.71% | -38.64% | -6.61% | -65.61x | |
| 944M | -40.36% | -40.47% | -70.72% | -11.67% | 4.51x | |
| 39.21M | -794.04% | -891.07% | -25.78% | -22.89% | 4.75x | |
| 1.48B | 16.37% | 17.21% | 14.72% | 10.64% | -2.06x | |
| 46.02M | -282.83% | -343.63% | -20.18% | -18.42% | 0.82x | |
| Average | 3.65B | -1,178.89% | -1,135.42% | -7.34% | 2.35% | -2.71x | |
| Weighted average by Cap. | 5.63B | -354.45% | -271.16% | 5.46% | 5.05% | -1.52x |
- Stock Market
- Stocks
- CATX Stock
- Sector Perspective Therapeutics, Inc.
- Financial comparisons
Choose MarketScreener Select your edition
All financial news and data tailored to specific country editions
